Iovance Biotherapeutics Inc (NASDAQ:IOVA) – Piper Jaffray Companies issued their Q1 2019 EPS estimates for Iovance Biotherapeutics in a research note issued to investors on Monday, April 29th, according to Zacks Investment Research. Piper Jaffray Companies analyst J. Catanzaro forecasts that the biotechnology company will post earnings per share of ($0.28) for the quarter. Piper Jaffray Companies currently has a “Overweight” rating and a $20.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Iovance Biotherapeutics’ Q2 2019 earnings at ($0.29) EPS, Q3 2019 earnings at ($0.30) EPS, Q4 2019 earnings at ($0.32) EPS, FY2019 earnings at ($1.18) EPS, Q1 2020 earnings at ($0.31) EPS, Q2 2020 earnings at ($0.31) EPS, Q3 2020 earnings at ($0.31) EPS, Q4 2020 earnings at ($0.33) EPS, FY2020 earnings at ($1.25) EPS, FY2021 earnings at ($1.29) EPS, FY2022 earnings at ($1.07) EPS and FY2023 earnings at ($0.53) EPS.
Several other equities analysts have also recently issued reports on IOVA. Chardan Capital reissued a “buy” rating on shares of Iovance Biotherapeutics in a research note on Wednesday, March 13th. Robert W. Baird boosted their price objective on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday. ValuEngine cut shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. B. Riley reissued a “buy” rating on shares of Iovance Biotherapeutics in a research note on Friday, April 5th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Iovance Biotherapeutics in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.13.
Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.01).
Large investors have recently bought and sold shares of the company. Advisor Group Inc. grew its stake in shares of Iovance Biotherapeutics by 58.6% during the 4th quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 3,000 shares during the period. Kalos Management Inc. acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter worth $93,000. Virtu Financial LLC acquired a new stake in Iovance Biotherapeutics in the 1st quarter valued at about $99,000. Great West Life Assurance Co. Can grew its stake in Iovance Biotherapeutics by 67.4% in the 4th quarter. Great West Life Assurance Co. Can now owns 14,538 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 5,853 shares during the last quarter. Finally, Moors & Cabot Inc. acquired a new stake in Iovance Biotherapeutics in the 1st quarter valued at about $126,000. 96.45% of the stock is currently owned by institutional investors and hedge funds.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
See Also: What are gap-up stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.